Last reviewed 2026-04-20 · How we verify

PF-06700841 30 mg (pf-06700841-30-mg)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Upper respiratory tract infection
• Nasopharyngitis
• Headache
• COVID-19
• Nausea
• Urinary tract infection
• Diarrhoea
• Fatigue
• Blood creatine phosphokinase increased
• Hypertension
• Alanine aminotransferase increased
• Cystitis

Key clinical trials

• Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease (PHASE2)
• A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) (PHASE2)
• Renal Impairment Study of PF-06700841 (PHASE1)
• A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis (PHASE2)
• Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids (PHASE1)
• Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata (PHASE2)
• A Study to Investigate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of PF-06700841 in Healthy Participants (PHASE1)
• Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• PF-06700841 30 mg CI brief — competitive landscape report
• PF-06700841 30 mg updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI